Novo Hits Back As Roche CEO Joins Catalent Takeover Opposition
Breaking with convention, Thomas Schinecker has said allowing the $16.5bn acquisition to go ahead would be “the wrong decision”. Novo Nordisk says otherwise.
Breaking with convention, Thomas Schinecker has said allowing the $16.5bn acquisition to go ahead would be “the wrong decision”. Novo Nordisk says otherwise.